ImmuCell (NASDAQ:ICCC) Stock Price Crosses Below Two Hundred Day Moving Average of $4.95

ImmuCell Co. (NASDAQ:ICCC)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.95 and traded as low as $4.46. ImmuCell shares last traded at $4.49, with a volume of 873 shares trading hands.

ImmuCell Stock Up 4.4 %

The firm has a market cap of $33.43 million, a P/E ratio of -8.39 and a beta of 0.58. The company’s 50-day simple moving average is $4.66 and its 200 day simple moving average is $4.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.71 and a quick ratio of 1.00.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.06) EPS for the quarter. ImmuCell had a negative net margin of 18.31% and a negative return on equity of 15.21%. The business had revenue of $7.26 million during the quarter.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Mesirow Financial Investment Management Inc. acquired a new position in shares of ImmuCell Co. (NASDAQ:ICCC) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned 0.16% of ImmuCell as of its most recent SEC filing. 13.47% of the stock is currently owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.